La Jolla whips up some love for iron overload drug with promising data snapshot
With revenue trickling in from its first product and an NDA in place for a second, La Jolla Pharmaceutical is ready to shine a bright light on the third candidate coming through its pipeline.
An interim analysis of a Phase II study suggests that LJPC-401 could significantly lower the excess iron levels in patients with hereditary hemochromatosis. The drug — a subcutaneous injection of synthetic human hepcidin — induced a mean reduction in TSAT from baseline of 42%, versus 6% on placebo (p<0.0001), marking a clear score on the primary endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
